Published in Drug Week, August 28th, 2009
Second Quarter Ended June 30, 2009
The Company recorded a net loss of $2.3 million, or $0.05 per share, for the second quarter 2009 compared to a net loss of $2.7 million, or $0.10 per share, in the second quarter 2008. Cash and cash equivalents totaled $2.9 million at June 30, 2009.
The decrease in net loss for the second quarter 2009 is due primarily to a 38% decrease in operating expenses to $1.6 million from $2.6 million in the second quarter 2008. The decline in operating expenses resulted from a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.